Scholarlink

Background <p>Gastric cancer (GC) remains an important global health challenge. GC ranks as the fourth most common cancer in India with regional variations in incidence. In Chennai, it ranks as the third most common cancer in men and the sixth most common in women. Studying the complex molecular markers expression of GC is very useful for the establishment of treatment strategies and increasing survival rates. This study aimed to comprehensively estimate the expression of E-Cadherin, p53, p16, and HER-2 in GC biopsies and their association with clinical features and survival.</p> Methods <p>Immunohistochemical analysis was performed on tissue biopsies obtained from 150 patients with GC at a tertiary care hospital in Chennai, Tamil Nadu, India, between 2015 and 2018. The patient’s survival was tracked for 10&#xa0;years.</p> Results <p>This is the first study of its kind to analyse the long term follow-up of GC patient’s survival and the expression of these biomarker. The 94.7% (142/150) of patients died during the follow-up. Tumor stage, location, and treatment modality significantly influenced patient survival. The combination of surgery and chemotherapy demonstrated an increase in survival rate. Loss of E-Cadherin expression was more common in poorly differentiated tumors. HER-2 overexpression was common in well-differentiated tumors and varied by tumor location, with higher rates in the body of stomach.</p> Conclusions <p>E-Cadherin, HER-2 may be interrelated with differentiation of GC. Significantly, longer overall survival was associated with HER-2-negative tumors, although statistical significance was attenuated following adjustment for stage, location, and treatment, each of these factors independently predicts survival in gastric cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A 10-Year Survival Perspective in Gastric Cancer: The Clinical Significance of E-Cadherin, P53, P16, and HER-2

  • 期刊论文

  • 发表日期：

    2026年5月27日

查看全文
  • Karthick Rajendran,
  • Kalaichelvi Kannan,
  • Theranirajan Ethirajan,
  • Priyadarshini Panneerselvam,
  • Sudha Venkatesh,
  • Chitra Ayyappan,
  • Arunkumar Ramachandran,
  • Muthukumaran Rajaram

摘要

Background

Gastric cancer (GC) remains an important global health challenge. GC ranks as the fourth most common cancer in India with regional variations in incidence. In Chennai, it ranks as the third most common cancer in men and the sixth most common in women. Studying the complex molecular markers expression of GC is very useful for the establishment of treatment strategies and increasing survival rates. This study aimed to comprehensively estimate the expression of E-Cadherin, p53, p16, and HER-2 in GC biopsies and their association with clinical features and survival.

Methods

Immunohistochemical analysis was performed on tissue biopsies obtained from 150 patients with GC at a tertiary care hospital in Chennai, Tamil Nadu, India, between 2015 and 2018. The patient’s survival was tracked for 10 years.

Results

This is the first study of its kind to analyse the long term follow-up of GC patient’s survival and the expression of these biomarker. The 94.7% (142/150) of patients died during the follow-up. Tumor stage, location, and treatment modality significantly influenced patient survival. The combination of surgery and chemotherapy demonstrated an increase in survival rate. Loss of E-Cadherin expression was more common in poorly differentiated tumors. HER-2 overexpression was common in well-differentiated tumors and varied by tumor location, with higher rates in the body of stomach.

Conclusions

E-Cadherin, HER-2 may be interrelated with differentiation of GC. Significantly, longer overall survival was associated with HER-2-negative tumors, although statistical significance was attenuated following adjustment for stage, location, and treatment, each of these factors independently predicts survival in gastric cancer.